Table 4.
Symptoms, drug application and CT of patients with RP RNA
| All patients (n = 25) | Positive times ⩽twice (n = 18) | Positive times >twice (n = 7) | P value | |
|---|---|---|---|---|
| Age – years | 47.6 ± 17.4 | 43.0 ± 16.9 | 59.6 ± 12.9 | <0.05 |
| Gender (male/female) – no. (%) | 10/15 (40.0/60.0) | 8/10 (44.4/55.6) | 2 /5(28.6/71.4) | 0.47 |
| Isolate-time – days | 15.8 ± 6.0 | 13.8 ± 4.7 | 20.9 ± 6.4 | <0.05 |
| Frequency of RNA detection – no. | 10.2 ± 4.2 | 8.2 ± 1.6 | 15.4 ± 4.2 | <0.001 |
| IgM positive – no. (%) | 4 (16.0) | 3 (16.7) | 1 (14.3) | 0.88 |
| IgG positive – no. (%) | 19 (76.0) | 13 (72.2) | 6 (85.7) | 0.48 |
| Symptoms – no. (%) | ||||
| Fever | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Cough | 3 (12.0) | 3 (16.7) | 0 (0.0) | 0.25 |
| Expectoration | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| Chest distress | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| Chest pain | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Sore throat | 2 (8.0) | 2 (11.1) | 0 (0.0) | 0.36 |
| Asthma | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Fatigue | 2 (8.0) | 2 (11.1) | 0 (0.0) | 0.36 |
| Muscle soreness | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| Nausea and vomiting | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| Diarrhoea | 2 (8.0) | 0 (0.0) | 2 (28.6) | <0.05 |
| Dizziness | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Headache | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| Rash | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Eye discomfort | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| Asymptomatic | 17 (68.0) | 12 (66.7) | 2 (28.6) | 0.82 |
| Drug application – no. (%) | ||||
| Antiviral drug | 10 (40.0) | 6 (33.3) | 4 (57.1) | 0.28 |
| Arbidol | 9 (36.0) | 6 (33.3) | 3 (42.9) | 0.66 |
| Antibiotic | 10 (40.0) | 6 (33.3) | 4 (57.1) | 0.28 |
| Moxifloxacin | 9 (36.0) | 5 (27.8) | 4 (57.1) | 0.17 |
| Cephalosporin antibiotics | 2 (8.0) | 1 (5.6) | 1 (14.3) | 0.47 |
| Amoxicillin | 2 (8.0) | 2 (11.1) | 0 (0.0) | 0.36 |
| Vitamin C | 5 (20.0) | 4 (22.2) | 1 (14.3) | 0.66 |
| Centrum | 1 (4.0) | 0 (0.0) | 1 (14.3) | 0.10 |
| Immunomodulator | 2 (8.0) | 1 (5.6) | 1 (14.3) | 0.47 |
| Diammonium glycyrrhizate | 2 (8.0) | 2 (11.1) | 0 (0.0) | 0.36 |
| Bronchodilator | 1 (4.0) | 0 (0.0) | 1 (14.3) | 0.10 |
| Acetylcysteine | 8 (32.0) | 6 (33.3) | 2 (28.6) | 0.82 |
| Digestive system drugs | 6 (24.0) | 3 (16.7) | 3 (42.9) | 0.17 |
| Ophthalmic | 2 (8.0) | 1 (5.6) | 1 (14.3) | 0.47 |
| Antihypertensive drugs | 6 (24.0) | 3 (16.7) | 3 (42.9) | 0.17 |
| Lipid-lowering drugs | 3 (12.0) | 1 (5.6) | 2 (28.6) | 0.11 |
| Antidiabetic drugs | 1 (4.0) | 0 (0.0) | 1 (14.3) | 0.10 |
| Diazepam | 7 (28.0) | 3 (16.7) | 4 (57.1) | <0.05 |
| Deanxit | 1 (4.0) | 0 (0.0) | 1 (14.3) | 0.10 |
| Antihistamine | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| Traditional Chinese medicine | ||||
| Lianhua Qingwen granules and capsules | 8 (32.0) | 6 (33.3) | 2 (28.6) | 0.82 |
| ELP enteric soft capsules | 2 (8.0) | 0 (0.0) | 2 (28.6) | <0.05 |
| Qiangli Pipa syrup | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| TCM prescriptions | 25 (100.0) | 18 (100.0) | 7 (100.0) | – |
| CT – no. (%) | ||||
| Normal | 6 (24.0) | 5 (27.8) | 1 (14.3) | 0.48 |
| Light GGO | 1 (4.0) | 0 (0.0) | 1 (14.3) | 0.10 |
| Patchy GGO | 10 (40.0) | 8 (44.4) | 2 (28.6) | 0.47 |
| Consolidation shadow | 2 (8.0) | 2 (11.1) | 0 (0.0) | 0.36 |
| Fibre streak shadow | 7 (28.0) | 4 (22.2) | 3 (42.9) | 0.30 |
| Nodular shadow | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| Patchy shadow | 4 (16.0) | 3 (16.7) | 1 (14.3) | 0.88 |
| Fibrosis foci | 3 (12.0) | 3 (16.7) | 0 (0.0) | 0.25 |
| Pleural thickening | 1 (4.0) | 0 (0.0) | 1 (14.3) | 0.10 |
| Pleural effusion | 1 (4.0) | 1 (5.6) | 0 (0.0) | 0.52 |
| Improved | 21 (84.0) | 15 (83.3) | 6 (85.7) | 0.88 |
ELP, eucalyptol, limonene and pinene; TCM, traditional Chinese medicine; CT, computed tomography; GGO, ground-glass opacity.
Plus–minus values are means ± s.d.